A combination of Complement component 1 Esterase INHibitor (C1INH) and lung surfactant or immunoglobulins for the treatment of respiratory disorders as Infant Respiratory Distress Syndrome (IRDS), Adult Respiratory Distress Syndrome (ARDS), and acute lung injury (ALI) was tested under several trials (7–9). Here, SERPING1 is linked to acute respiratory distress syndrome.